Jeff Hutchins, PhD, discusses current clinical trials that are investigating whether some patients with non-small cell lung cancer may qualify for an immune-oncology therapy treatment regimen that is...
Craig A. Dionne, PhD, CEO of GenSpera, describes some of the drawbacks associated with common cancer treatments. Many types of drug therapies, like antiangiogenics and immunotherapies, may only be effective...
